Medication info
Starova Tablet 10mg (Rosuvastatin Calcium)

Starova Tablet 10mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
BC World Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 201000986 · Approved 2010.01.28

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.
Children's dosage
Ages 10 to 17 years: The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or longer. Safety and efficacy in children under 10 years of age have not been established.

Ingredients

Manufacturer
BC World Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used as an adjunct when dietary and exercise interventions alone do not adequately control primary hypercholesterolemia and mixed dyslipidemia. It is also administered in combination with other lipid-lowering therapies for patients with homozygous familial hypercholesterolemia and lowers total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, thereby delaying the progression of atherosclerosis. It is applicable in pediatric patients with familial hypercholesterolemia to aid in reducing cholesterol levels. This drug is also used as an adjunct to diet for patients with primary dysbetalipoproteinemia and has the effect of reducing the risk of cardiovascular diseases like stroke, myocardial infarction, and the need for vascular interventions. This medication helps improve vascular health and aids in cholesterol management.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.

Children's dosage

Ages 10 to 17 years: The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or longer. Safety and efficacy in children under 10 years of age have not been established.

Precautions

This medication should not be used in certain patients. For example, it should be avoided in patients with allergies to any components of this medication, severe liver disease, or myopathies. Furthermore, women with very poor renal function, those who are pregnant or breastfeeding, and women of childbearing age who do not employ adequate contraception should also avoid this medication. This drug contains lactose, so caution is needed for those with lactose intolerance. Regular monitoring of liver function and muscle health is required while using this drug. Individuals who consume large amounts of alcohol or have a history of liver disease should exercise extra caution, and any symptoms of muscle pain or weakness should prompt immediate consultation with a physician. This medication may interact with other drugs, so it is essential to inform your healthcare provider about any current medications you are taking. Co-administration with certain drugs could increase the blood concentration of this medication, raising the risk of muscle damage. Pregnant women or those planning to become pregnant should not use this medication, and if pregnancy occurs while using it, discontinuation should happen immediately. Breastfeeding women should also avoid this medication. In case of overdose, there is no specific antidote, so treatment should be symptomatic, and monitoring of liver function and muscle enzyme levels should be conducted carefully. During treatment with this medication, symptoms such as dizziness or headaches may occur, so caution is required when driving or operating machinery. Finally, this medication may rarely cause severe skin reactions, liver damage, or muscle injury in some patients, so any unusual symptoms must be reported to healthcare providers immediately.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular muscle weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, drug-induced lichenoid rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can be sensitive to air and moisture and should be stored in a tightly closed container. The storage temperature should be kept between 1 degree Celsius and 30 degrees Celsius at room temperature. Proper storage will help maintain the efficacy of the drug over time.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.